Core Viewpoint - The article discusses the rise of GLP-1 receptor agonists, particularly semaglutide (Ozempic and Wegovy), as effective treatments for type 2 diabetes and obesity, highlighting their popularity driven by social media and celebrity endorsements [4][6][10]. Group 1: Drug Development and Approval Timeline - The first GLP-1 drug, liraglutide (Victoza), was approved by the FDA in 2010 for blood sugar control in diabetes patients [6]. - Semaglutide was introduced in 2017 as Ozempic, initially for type 2 diabetes, and later as Wegovy for obesity in 2021, showing an average weight loss of about 15% after one year of use [6][16]. - The FDA approved semaglutide for weight management in 2021, and it was included in China's National Medical Insurance Directory in 2021 [16]. Group 2: Market Impact and Popularity - Since 2022, semaglutide has gained immense popularity, becoming known as a "celebrity weight loss injection" due to endorsements from figures like Elon Musk and Donald Trump [7][10]. - The demand for Wegovy surged, leading to shortages of both Wegovy and its sister product Ozempic, which is primarily used for diabetes treatment [10][12]. - Social media platforms have seen millions of views on content related to the weight loss effects of semaglutide, indicating a significant public interest [10][12]. Group 3: Mechanism of Action - GLP-1 is a hormone that helps lower blood sugar levels by promoting insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying, which also contributes to weight control [30]. - The development of GLP-1 receptor agonists is based on the observation that both diabetic and non-diabetic obese patients have reduced GLP-1 secretion and action [30][31]. Group 4: Usage Guidelines and Side Effects - Semaglutide is available in both injectable and oral forms, with specific dosing guidelines for initiation and maintenance [19][22]. - Common side effects include gastrointestinal issues such as nausea and vomiting, which may decrease as the body adjusts to the medication [28].

We're back on Morning Trade Live. Let's focus on Nova Nordics. The stock was downgraded today at Morgan Stanley.More on that coming up in a bit. The weight loss drug trade has lost some luster. Check out this comparison chart of Nova Nordisk and Eli Liy over the past year.Both stocks are down over the last 12 months. Novo down more than 35% during that time frame. And that is the focus of the morning trade.Joining us now for a closer look at Nova Nordisk is Schwab network host Marley Kaden. Very good mornin ...

该公司表示，Wegovy在现金支付渠道的渗透率低于预期，主要受到仿制药持续冲击影响。此外，旗舰 糖尿病药物Ozempic（注：中文商品名为"诺和泰"，司美格鲁肽的糖尿病适应症制剂）也面临美国市场 竞争加剧的压力。 诺和诺德将于8月6日发布二季度财报，新华财经注意到此前已有市场机构表示对公司业绩担忧，此次提 前发布业绩预警确定了市场猜想。 诺和诺德29日同时宣布，任命Maziar Mike Doustdar 为新任总裁兼首席执行官，该任命将于8月7日生 效。 新华财经北京7月30日电（可达）截至29日美股收盘，减肥药概念板块大跌，美股丹麦药企诺和诺德股 价大跌超21%。 | 诺和诺德 NVO | | | | --- | --- | --- | | 54. 990 | -14.010 | -20.30% | | 盘前现价 | 53.970盘前涨幅 | -21.783% | | 盘前涨跌 | -15.030美东时间 | 10:29 | | 卖价 | | | 诺和诺德美股盘前发布业绩预警，大幅下调2025年全年销售和营业利润增长预期，主要原因是旗舰减肥 药物Wegovy（注：中文商品名为"诺和盈"，司美格鲁肽的减肥适 ...

8年前，27岁的安德鲁·杜杜姆（Andrew Dudum）和他人合作创立线上药品销售平台Hims & Hers。现如今，随着减肥注射剂的走红，他成为最新一位借此实现财富暴涨的创业者。 助力股价飙升的另一因素是：4月29日，Hims & Hers与丹麦制药公司诺和诺德（Novo Nordisk）达成合 作，通过自己的在线药房销售后者的明星减肥药物Wegovy（中文商品名诺和盈）。 算上Hims & Hers，目前全美仅有三家远程医疗供应商获准销售该药物。诺和诺德是Wegovy和Ozempic （中文商品名诺和泰）的生产商，其中Ozempic最初用于治疗2型糖尿病。 今年2月，美国食品药品监督管理局（FDA）宣布禁止像Hims & Hers这样的远程医疗公司自制诺和诺德 减重药的仿制版本，其股价应声下挫。但合作消息释出后，Hims & Hers股价累计上涨73%，成功扭转 暴跌态势。此前，由于热门减重药物突然火爆导致司美格鲁肽（semaglutide）等关键成分短缺，包括 Hims & Hers在内的多家公司曾一度获准生产和销售这类药物。 根据《福布斯》估算，近期股票的亮眼表现让现年36岁的杜杜姆身家攀升至11亿 ...

凭借其明星产品GLP-1药物，诺和诺德在2025年第一季度继续展现了强劲的业绩增长态 势。 2024年，诺和诺德的司美格鲁肽（含Ozempic、Wegovy、Rybelsus）仅以不到两亿美元 的销售额差距，排在默沙东K药之后，与全球"药王"宝座失之交臂。 2025年第一季度，司 美格鲁肽全球销售额终于超过K药，暂时坐上了全球"药王"宝座。 周三（5月7日）欧股盘前，丹麦制药公司诺和诺德在官网发布了第一季度业绩报告。 报告显示，诺和诺德在今年头三个月间实现了290.34亿丹麦克朗（约合44亿美元，按实时 汇率计算，下同）的净利润，同比增长14%，高于分析师原先预测的278亿丹麦克朗。报告 还显示，诺和诺德第一季度的总收入为780.87亿丹麦克朗（约112.16亿美元），同比上升 18%。 按地域分布来看，2025年一季度，美国市场收 入443.16亿丹麦克朗（约63.65亿美元）， 同比增长17%，中国市场收入达到56.22亿丹麦克朗（约8.07亿美元），实现了22%的同 比增长。 分项中，用于治疗2型糖尿病的Ozempic（诺和泰）的季度销售额为327.21亿丹麦克朗 （约47.00亿美元），同比增长15% ...